BBNX Stock Forecast & Price Target

Beta Bionics Inc. has demonstrated strong financial performance, reporting Q3'25 revenue of $27.3 million, reflecting a significant year-over-year growth of 63.3% and exceeding previous estimates by $3.8 million. The company has increased its revenue forecasts for 2025 and 2026 to $97.5 million and $136 million, respectively, indicating a positive growth trajectory bolstered by robust new patient starts and a higher revenue mix from pharmacy sales. Furthermore, the expansion into the insulin pump market, particularly with new patient conversions from multiple daily injections, positions Beta Bionics favorably for sustained top-line growth moving forward.

Beta Bionics faces significant challenges that could hinder its financial performance, including potential difficulties in gaining market share with its iLet product due to competitive pressures and the need for additional investment if clinical development timelines are pushed back. The company's recent EBITDA loss of $12.2 million was substantially worse than expectations, raising concerns about its financial sustainability and the reliance on a pharmacy channel that is expected to experience only slight improvements in new starts. Additionally, uncertainties surrounding Medicare reimbursement models and the potential for increased shareholder dilution further contribute to a negative outlook for the company's financial future.